Technology
Health
Biotechnology
Sierra Oncology
$1.899876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.03 (-1.56%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell SRRA and other stocks, options, ETFs, and crypto commission-free!
About
Sierra Oncology, Inc. Common Stock, also called Sierra Oncology, is a clinical stage drug development company of therapeutics for the treatment of patients with cancer. Read More It engages in the business of researching, developing, and commercializing therapies for the treatment of patients with cancer. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.
CEO
Employees
79
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
140.55M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
454.01K
High Today
$1.93
Low Today
$1.89
Open Price
$1.93
Volume
58.34K
52 Week High
$3.70
52 Week Low
$1.05
Collections
Technology
Health
Biotechnology
Cancer Prevention
Medical
Therapy
2015 IPO
Canada
News
MarketBeatMar 11
Stock Price, News, & Analysis for Sierra Oncology
Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of t...
PR NewswireFeb 28
Sierra Oncology Reports 2018 Year End Results
- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER, Feb. 28, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today reported its financial and operational results for the year ended December 31, 2018. "In 2018, with our opportunistic acquisition of the...
Simply Wall StFeb 21
Have Insiders Been Buying Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So we’ll take a look at whether insiders have been buying or selling shares in Sierra Oncology, Inc. (NASDAQ:SRRA). What Is Insider Buying? Most investors know that it is quite perm...
Price Paid on Robinhood
15% Lower
Right Now
52 Week Low
$1.05
Average Price Paid
$2.23
52 Week High
$3.70
Earnings
-$0.22
-$0.20
-$0.18
-$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, Pre-Market